Acurx Pharmaceuticals LLC (ACXP) - Net Assets
Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) has net assets worth $3.64 Billion USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.11 Billion) and total liabilities ($2.47 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Acurx Pharmaceuticals LLC (ACXP) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.64 Billion |
| % of Total Assets | 59.57% |
| Annual Growth Rate | -5.58% |
| 5-Year Change | -77.23% |
| 10-Year Change | N/A |
| Growth Volatility | 176.79 |
Acurx Pharmaceuticals LLC - Net Assets Trend (2019–2024)
This chart illustrates how Acurx Pharmaceuticals LLC's net assets have evolved over time, based on quarterly financial data. Also explore how large is Acurx Pharmaceuticals LLC's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Acurx Pharmaceuticals LLC (2019–2024)
The table below shows the annual net assets of Acurx Pharmaceuticals LLC from 2019 to 2024. For live valuation and market cap data, see Acurx Pharmaceuticals LLC market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $615.12K | -86.82% |
| 2023-12-31 | $4.67 Million | -36.20% |
| 2022-12-31 | $7.32 Million | -41.06% |
| 2021-12-31 | $12.41 Million | +359.37% |
| 2020-12-31 | $2.70 Million | +229.52% |
| 2019-12-31 | $819.85K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Acurx Pharmaceuticals LLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5812138200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $17.03K | 2.77% |
| Other Components | $67.92 Million | 11041.74% |
| Total Equity | $615.12K | 100.00% |
Acurx Pharmaceuticals LLC Competitors by Market Cap
The table below lists competitors of Acurx Pharmaceuticals LLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Multi-Usage Holdings Bhd
KLSE:9539
|
$5.45 Million |
|
Seraphim Space Investment Trust PLC
LSE:SSIT
|
$5.45 Million |
|
D.T.C. Industries Public Company Limited
BK:DTCI
|
$5.45 Million |
|
Alfa Financial Software Holdings PLC
LSE:ALFA
|
$5.45 Million |
|
NGX Ltd
AU:NGX
|
$5.45 Million |
|
DTCOM - Direct to Company S.A
SA:DTCY3
|
$5.45 Million |
|
Danish Aerospace Company A/S
CO:DAC
|
$5.45 Million |
|
Tedea Technological Development and Automation Ltd
TA:TEDE
|
$5.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Acurx Pharmaceuticals LLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,666,685 to 615,121, a change of -4,051,564 (-86.8%).
- Net loss of 14,103,103 reduced equity.
- New share issuances of 6,405,757 increased equity.
- Other factors increased equity by 3,645,782.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.10 Million | -2292.74% |
| Share Issuances | $6.41 Million | +1041.38% |
| Other Changes | $3.65 Million | +592.69% |
| Total Change | $- | -86.82% |
Book Value vs Market Value Analysis
This analysis compares Acurx Pharmaceuticals LLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.99x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.26x to 2.99x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.72 | $2.16 | x |
| 2020-12-31 | $5.45 | $2.16 | x |
| 2021-12-31 | $24.30 | $2.16 | x |
| 2022-12-31 | $13.53 | $2.16 | x |
| 2023-12-31 | $7.37 | $2.16 | x |
| 2024-12-31 | $0.72 | $2.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Acurx Pharmaceuticals LLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2292.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 6.27x
- Recent ROE (-2292.74%) is below the historical average (-627.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -723.45% | 0.00% | 0.00x | 3.09x | $-6.01 Million |
| 2020 | -170.27% | 0.00% | 0.00x | 1.19x | $-4.87 Million |
| 2021 | -102.18% | 0.00% | 0.00x | 1.07x | $-13.92 Million |
| 2022 | -165.31% | 0.00% | 0.00x | 1.28x | $-12.82 Million |
| 2023 | -312.38% | 0.00% | 0.00x | 1.65x | $-15.04 Million |
| 2024 | -2292.74% | 0.00% | 0.00x | 6.27x | $-14.16 Million |
Industry Comparison
This section compares Acurx Pharmaceuticals LLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Acurx Pharmaceuticals LLC (ACXP) | $3.64 Billion | -723.45% | 0.68x | $5.45 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more